Skip to content

Effect of weifuchun on JAK2/STAT3 pathway in gastric precancerous lesions

Effect of weifuchun on JAK2/STAT3 pathway in gastric precancerous lesions

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061717
Enrollment
Unknown
Registered
2022-07-01
Start date
2022-07-15
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Precancerous lesion of stomach

Interventions

4(1. Chronic superficial gastritis 2. Chronic atrophic gastritis 3. Intestinal metaplasia 4. Atypical hyperplasia):medication

Sponsors

Zhejiang Medical Association
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed by gastroscopy and pathological diagnosis, and meeting the diagnostic criteria of chronic superficial gastritis and gastric precancerous lesions; 2. The age is 18-75 years old; 3. Patients who have not taken other drugs that affect this clinical study recently.

Exclusion criteria

Exclusion criteria: 1. Patients with pathological diagnosis of gastric cancer or malignant tumor coexisting with pathology; 2. Patients with severe mental illness and experimental drug allergy or allergic reaction during taking medicine; 3. Patients with serious diseases of liver, kidney, brain and blood system; 4. Those who fail to take the medicine for the full course of treatment or cannot judge the curative effect after treatment; 5. The patient has not taken any drugs that have influence on the study recently.

Design outcomes

Primary

MeasureTime frame
The positive expression rate of JAk2, STAT3 and BCL2;

Countries

china

Contacts

Public ContactXie Xicheng

Xixi Hospital of Hangzhou

hzxxh003@126.com+86 15355013835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026